Related Experiment Video
Updated: Dec 15, 2025
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
5.1K
Ligandrol (LGD-4033)-Induced Liver Injury
Mary Barbara1,2, Sadhna Dhingra3, Ayse L Mindikoglu1,2
1Section of Gastroenterology and Hepatology, Margaret M. and Albert B. Alkek Department of Medicine, Baylor College of Medicine, Houston, TX.
ACG Case Reports Journal
|July 9, 2020
Summary
A 32-year-old man experienced severe liver injury from Ligandrol (LGD-4033), a selective androgen receptor modulator. Liver biopsy confirmed drug-induced liver injury with cholestatic hepatitis and fibrosis, highlighting potential risks of this supplement.
Area of Science:
- Hepatology
- Pharmacology
- Toxicology
Background:
- Selective androgen receptor modulators (SARMs) like Ligandrol (LGD-4033) are increasingly available online.
- Concerns exist regarding the safety and potential adverse effects of SARMs on liver function.
- This case highlights the need for awareness of SARM-associated hepatotoxicity.
Observation:
- A 32-year-old male presented with severe drug-induced liver injury.
- The patient reported recent use of Ligandrol (LGD-4033), an over-the-counter SARM.
- Symptoms indicated significant liver damage.
Findings:
- Liver biopsy confirmed severe cholestatic hepatitis.
- Histopathology revealed mild portal, periportal, and perisinusoidal fibrosis.
- The findings were consistent with drug-induced liver injury attributed to Ligandrol (LGD-4033) use.
Implications:
- This case underscores the potential hepatotoxicity of Ligandrol (LGD-4033) and other SARMs.
- Healthcare providers should be vigilant for SARM-induced liver injury in patients using these substances.
- Further research is warranted to understand the long-term liver safety profile of SARMs.
